Corollary 1 — subsidy budget determines which payment scheme has the lower price
ProvedRareDisease.Endogenous.corollary_1comparative-staticsdrug-pricingp2o-batch-pfp2ap2o-gran-per-chapterp2o-plan-paperp2o-v1subsidy
Let be the R&D cost scale and the subsidy budget. The policy , where , is optimal under both sales-based and outcome-based payment, so optimal policies exist in both schemes. For every optimal policy in each scheme and every associated manufacturer best response, write and for the sales-based and outcome-based prices. Then
This compares actual optimal prices in the two games, including the threshold case.
Formalization Note Corollary 1(2) prints a strict “higher price” claim for . At equality the prices coincide, so the formal statement corrects that boundary slip. The paper's unconstrained efficacy choice is retained; can exceed one in the high-budget regime.
Preamble
import Mathlib import Definitions.Def_RareDisease_Endogenous_Setting
Formal statement
namespace RareDisease.Endogenous
/-- Corollary 1, pp. 13–14, with the equality case corrected. -/
theorem corollary_1 (k B : ℝ) (hk : 0 < k) (hB : 0 < B) :
IsOptimalA k B (alphaStar k B) 0 ∧
IsOptimalB k B (alphaStar k B) 0 ∧
∀ α β α' β' : ℝ, IsOptimalA k B α β → IsOptimalB k B α' β' →
∀ x ∈ BRA k α β, ∀ y ∈ BRB k α' β',
(B < k - 1 / 8 → x.1 < y.1) ∧
(k - 1 / 8 < B → y.1 < x.1) ∧
(B = k - 1 / 8 → x.1 = y.1) := by sorry
end RareDisease.Endogenous
Source
Olsder, Martagan, Tang, Improving Access to Rare Disease Treatments: Optimal Subsidies, Pricing, and Payment, SSRN working paper 3481150 (version of 2019-11-13), p. 13, §4.2, Corollary 1, and p. 14, paragraph after it
Human review
Confirmed by the mission captain (proposal self-audit).
Confirmed by the moderator at approval.